2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development

Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs. Furthermore, we highlight ongoing challenges related to their clinical optimization, the development of rational sequencing strategies, and the identification of predictive biomarkers. Significance: The development and utilization of ADCs have allowed for relevant improvements in the prognosis of multiple cancer types. Concomitantly, the rise of ADCs in oncology has produced several challenges, including the prediction of their activity, their utilization in sequence, and minimization of their side effects, that still too often resemble those of the cytotoxic molecule that they carry. In this review, we retrace 40 years of development in the field of ADCs and delve deep into the mechanisms of action of these complex therapeutics and reasons behind the many achievements and failures observed in the field to date.

Raffaele Colombo,1 Paolo Tarantino,2,3,4 Jamie R Rich,1 Patricia M LoRusso,5 Elisabeth G E de Vries6

  1. ADC Therapeutic Development, Zymeworks Inc., Vancouver, Canada.
  2. Dana-Farber Cancer Institute, Boston, Massachusetts.
  3. Harvard Medical School, Boston, Massachusetts.
  4. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  5. Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut.
  6. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Source: Colombo R., Tarantino P., Rich JR. et al. The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development. Cancer Discov. 2024 Oct 23:OF1-OF20. doi: 10.1158/2159-8290.CD-24-0708.